For the quarter ending 2026-03-31, IRMD had $922,756 increase in cash & cash equivalents over the period. -$3,666,602 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Net income | -10,220,042 | 5,576,652 | 10,461,390 | 19,234,026 |
| Allowance for credit losses | 123,125 | -50,236 | -32,889 | -94,535 |
| Loss on disposal of property and equipment | - | -32,991 | -1,161 | -3,871 |
| Provision for excess and obsolete inventory | -11,667 | 19,146 | 7,521 | 87,641 |
| Depreciation & amortization | -330,320 | 383,722 | 401,598 | 817,656 |
| Stock-based compensation | -1,538,764 | 666,082 | 1,556,682 | 2,524,536 |
| Deferred income taxes, net | 534,987 | -134,872 | -263,115 | 697,652 |
| Accounts receivable | -3,430,434 | 2,885,922 | 332,512 | -1,762,075 |
| Inventory | -896,911 | 559,684 | 871,227 | -3,126,046 |
| Prepaid income taxes | -1,152,400 | 1,373,004 | -206,604 | - |
| Prepaid expenses and other current assets | 395,350 | -827,625 | 411,275 | 320,233 |
| Other assets | -28,462 | 9,875 | 5,587 | 17,463 |
| Accounts payable | -75,069 | 432,494 | 4,575 | -861,618 |
| Accrued payroll and benefits | -1,451,420 | 861,031 | -561,611 | 996,653 |
| Other accrued taxes | -19,209 | -28,437 | 161,646 | 59,757 |
| Warranty reserve | - | 15,804 | 2,952 | 806 |
| Deferred revenue | -1,173,053 | 141,843 | 1,336,210 | -111,052 |
| Other current liabilities | 150,000 | 0 | -150,000 | -100,000 |
| Accrued income taxes | -712,970 | 2,800,970 | - | -786,051 |
| Net cash provided by operating activities | -10,734,428 | 6,986,075 | 12,038,353 | 25,624,463 |
| Purchases of property and equipment | -7,067,826 | 1,137,612 | 6,333,214 | 8,005,033 |
| Capitalized intangible assets | -467,767 | 125,943 | 407,824 | 811,753 |
| Net cash used in investing activities | 7,535,593 | -1,263,555 | -6,741,038 | -8,816,786 |
| Dividends paid | -3,929,741 | 2,162,591 | 4,323,150 | 13,677,426 |
| Proceeds from exercises of stock options | - | - | - | 29,618 |
| Taxes paid related to the net share settlement of equity awards | -191,850 | 29,559 | 212,291 | 688,160 |
| Net cash used in financing activities | 4,121,591 | -2,192,150 | -4,535,441 | -14,335,968 |
| Net increase (decrease) in cash and cash equivalents | 922,756 | 3,530,370 | 761,874 | 2,471,709 |
| Cash and cash equivalents, beginning of period | 56,526,151 | 52,233,907 | - | - |
| Cash and cash equivalents, end of period | 56,374,000 | 56,526,151 | - | - |
IRADIMED CORP (IRMD)
IRADIMED CORP (IRMD)